|This message contains images. If you don't see images, click here to view.|
Advertise in this news brief.
Register now for the FSP Summer Anatomic Pathology Conference
Register here or go to www.flpath.org and click on the Summer Meeting tab to secure all information on speakers, program, hotel, Boca Raton and registration.
Andrew E. Rosenberg, M.D.
University of Miami Health Service
William Westra, M.D.
Johns Hopkins Medical Institute
Cesar Moran, M.D.
The University of Texas MD Anderson Cancer Center
6 hours of sleep: Is it enough for some patients?
Obtaining sufficient sleep is a crucial component of proper health maintenance. Some authors have gone so far as to recommend that sleep be considered an additional "vital sign" to be assessed at each healthcare provider visit. There are multiple facets to a comprehensive sleep evaluation for an individual patient; however, one of the most important measures is average sleep duration each night. Although all might agree on the importance of total sleep time, it isn't clear what the nightly target should be. In other words, how much sleep is enough for your patient? Before providing an answer to this surprisingly complex question, it's worth taking the time to review the science of health outcomes as they relate to sleep.
Tumor genomics: Sequence normal tissue, too
The standard approach of analyzing malignant tumors for unique genetic mutations to target therapy may not be sufficient and may, in fact, lead to inappropriate treatment, researchers said. For accuracy, tumor genomes should also be compared with matched samples of DNA from patient's noncancerous tissue, concluded investigators led by Sian Jones, Ph.D., of Personal Genome Diagnostics, in Baltimore, who reported their findings online in Science Translational Medicine.
Medical schools reboot for 21st century
Medicine has changed a lot in the past 100 years. But medical training hasn't — until now. Spurred by the need to train a different type of doctor, some top medical schools around the U.S. are tearing up the textbooks and starting from scratch. Most medical schools still operate under a model pioneered in the early 1900s by an educator named Abraham Flexner. The University of Michigan is one of many med schools in the midst of a major overhaul of their curricula.
Your next prescription could be a genome sequence
At Advances in Genome Biology and Technology, one speaker told attendees that the use of genome sequencing to improve patient care is no longer a far-off goal — it's happening today. While you won't encounter genome sequencing on an average visit to the ER, there are certain clinical areas where this technology has indeed become routine: cancer, pediatric care, the diagnosis and treatment of ultra rare diseases, and a few others.
As CMS becomes lenient, providers tackle patient engagement
While patient engagement remains a top priority for many medical organizations across the country, the Centers for Medicare & Medicaid Services released a proposed ruling modifying meaningful use requirements and specifically relenting on a major patient engagement objective. Previously, stage 2 meaningful use requirements called for 5 percent of a provider's patient base to access, download and/or transmit their electronic health information, but now this objective has been changed for the years 2015 to 2017 in the proposed ruling.
Miss an issue of Pathology Today? Click here to visit the Pathology Today archive page.
FSU, Sarasota Memorial to start residency program
Knowing that most doctors who go to school in Florida don't practice in the state if they do their residencies elsewhere, Florida State University and Sarasota Memorial Hospital have agreed to start an internal medicine residency program in early 2017. The school and hospital signed the deal in March.
New collaboration brings comprehensive genomic profiling to UC Davis
The UC Davis Comprehensive Cancer Center and the Department of Pathology and Laboratory Medicine have entered into a collaboration with Foundation Medicine, a leading molecular information company. The collaboration brings comprehensive genomic profiling into standard of care at UC Davis, allowing physicians to prescribe the most effective, targeted cancer treatments to patients based on the genomic information specific to each individual's cancer.
New breast cancer gene identified
A new breast cancer gene has been identified in a study led by Women's College Hospital (WCH) researcher Dr. Mohammad Akbari, who is also an assistant professor with the Dalla Lana School of Public Health at the University of Toronto. The study, which was published online in Nature Genetics, describes how mutations in a gene called RECQL are strongly linked to the onset of breast cancer in two populations of Polish and French-Canadian women.
Disclaimer: The authors, editors, and the Florida Society of Pathologists (FSP) Executive Committee affiliated with "Florida Pathology Today" e-Newsletter cannot and do not warrant the completeness, accuracy, non-infringement, merchantability, timeliness or fitness for a particular purpose of the information or views contained within this publication, or available through the links provided within articles contained within this publication.
FSP has no control over and does not officially endorse the content of the information available on the links contained in the "Florida Pathology Today" or links imbedded in articles within the "Florida Pathology Today." These links are provided as a courtesy only. Linked sites are not a part of the "Florida Pathology Today." The owners of those linked sites, and not FSP, own the intellectual property rights to the material on the linked sites. FSP cannot certify the accuracy of material published on linked sites. Additionally, the contents of this e-Newsletter and the above referenced links, including any advice, suggestions, and/or recommendations have NOT been generated as part of any professional evaluation.
The authors, editors, webmasters, and the FSP Board of Directors affiliated with the "Florida Pathology Today" e-Newsletter shall not be liable to anyone for any loss or injury caused in whole or in part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting or delivering this e-Newsletter and any information included in this e-Newsletter.
Under no circumstances will the authors, editors, webmasters, and the FSP Board of Directors affiliated with the "Florida Pathology Today" be liable to you or anyone else for any decision made or any action taken by you or anyone else in reliance on such information or view, or for any incidental, consequential, special, or similar damages even if advised of the possibility of such damages.
The above warranties are the only warranties of any kind either expressed or implied, including warranties of merchantability or fitness for any particular purpose.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063